We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
-15.71%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$329M
AUM Growth
+$44.4M
Cap. Flow
+$128M
Cap. Flow %
38.78%
Top 10 Hldgs %
82.37%
Holding
31
New
9
Increased
7
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$95.6M
2
RGLS
Regulus Therapeutics
RGLS
+$7.33M
3
XLRN
Acceleron Pharma
XLRN
+$5.04M
4
RGNX icon
Regenxbio
RGNX
+$4M
5
EPZM
Epizyme, Inc
EPZM
+$2.26M

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$4.88M
2
SCYX icon
SCYNEXIS
SCYX
+$2.23M
3
BITI
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
+$1.9M
4
AGRX
Agile Therapeutics
AGRX
+$428K
5
QTNT
Quotient Limited Ordinary Shares
QTNT
+$111K

Sector Composition

Rank Sector Weight
1 Healthcare 58.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIMT
1
DELISTED
Aimmune Therapeutics
AIMT
$104M 31.43%
+4,087,900
New +$95.6M
KDNY
2
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$40.8M 12.39%
421,347
– –
LRMR icon
3
Larimar Therapeutics
LRMR
$416M
$25.9M 7.87%
67,608
– –
ADAP
4
DELISTED
Adaptimmune Therapeutics
ADAP
$21M 6.39%
1,757,268
– –
UAM
5
DELISTED
Universal American Corp
UAM
$19.3M 5.85%
2,814,883
– –
AERI
6
DELISTED
Aerie Pharmaceuticals
AERI
$16.1M 4.88%
906,317
+101,100
+13% +$1.83M
EPZM
7
DELISTED
Epizyme, Inc
EPZM
$13M 3.94%
1,009,795
+111,932
+12% +$2.26M
RGLS
8
DELISTED
Regulus Therapeutics
RGLS
$11.4M 3.48%
14,586
+7,138
+96% +$7.33M
ALDR
9
DELISTED
Alder Biopharmaceuticals
ALDR
$11.3M 3.43%
344,770
– –
ARDX icon
10
Ardelyx
ARDX
$1.24B
$8.94M 2.71%
517,290
– –
OREX
11
DELISTED
Orexigen Therapeutics, Inc.
OREX
$8.91M 2.71%
422,505
+2,500
+0.6% +$85.7K
NSTG
12
DELISTED
NanoString Technologies, Inc.
NSTG
$7.43M 2.26%
464,486
– –
XLRN
13
DELISTED
Acceleron Pharma
XLRN
$4.95M 1.5%
198,717
+167,617
+539% +$5.04M
BDSI
14
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$4.9M 1.49%
881,562
+169,284
+24% +$1.25M
QTNT
15
DELISTED
Quotient Limited Ordinary Shares
QTNT
$3.79M 1.15%
7,281
-178
-2% -$111K
ANAC
16
CALL
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$3.65M 1.11%
+31,000
New +$4.05M
ANAC
17
PUT
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$3.65M 1.11%
+31,000
New +$4.05M
RGNX icon
18
Regenxbio
RGNX
$623M
$3.45M 1.05%
+156,741
New +$4M
NVET
19
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$2.58M 0.78%
708,332
– –
SCYX icon
20
SCYNEXIS
SCYX
$37M
$2.46M 0.75%
4,215
-3,637
-46% -$2.23M
EPZM
21
PUT
DELISTED
Epizyme, Inc
EPZM
$1.93M 0.59%
+150,000
New +$3.03M
BDSI
22
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.72M 0.52%
+310,000
New +$2.29M
BDSI
23
PUT
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.72M 0.52%
+310,000
New +$2.29M
RGLS
24
CALL
DELISTED
Regulus Therapeutics
RGLS
$1.64M 0.5%
+2,083
New +$2.14M
RGLS
25
PUT
DELISTED
Regulus Therapeutics
RGLS
$1.64M 0.5%
+2,083
New +$2.14M
1
2

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q3 2015 Portfolio in Review

As of Q3 2015, Foresite Capital Management II held 31 positions worth $329M, up 16% from $285M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Foresite Capital Management II deployed $128M of net new capital in Q3 2015, opening 9 new positions and adding to 7 existing holdings. Its largest new stake was Aimmune Therapeutics: 4,087,900 shares worth $104M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was SCYNEXIS, an estimated $2.23M trimmed.

  • Foresite Capital Management II's largest Q3 2015 buy was Aimmune Therapeutics: 4,087,900 shares worth $104M.
  • Foresite Capital Management II added most to Regulus Therapeutics in Q3 2015, an estimated $7.33M increase.
  • Foresite Capital Management II's biggest Q3 2015 reduction was SCYNEXIS, cutting an estimated $2.23M.
  • Foresite Capital Management II fully exited Juno Therapeutics, Inc. in Q3 2015, selling an estimated $4.88M.
  • Foresite Capital Management II's ten largest holdings make up 82% of its $329M portfolio in Q3 2015.
  • Foresite Capital Management II opened 9 new positions and closed 2 in Q3 2015.
  • Foresite Capital Management II's portfolio value rose 16% quarter-over-quarter to $329M.

Based on Foresite Capital Management II's 13F filing for Q3 2015, filed 13 Nov 2015.